<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Notch Signaling &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/notch-signaling/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 11 Oct 2026 13:45:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Notch Signaling &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Single-Cell Atlas Reveals DLL3 as a Drug Target in Aggressive Cervical Cancer</title>
		<link>https://bioengineer.org/single-cell-atlas-reveals-dll3-as-a-drug-target-in-aggressive-cervical-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sun, 11 Oct 2026 13:45:51 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[DLL3]]></category>
		<category><![CDATA[immunosuppression]]></category>
		<category><![CDATA[neuroendocrine carcinoma of the cervix]]></category>
		<category><![CDATA[Notch Signaling]]></category>
		<category><![CDATA[organoids]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[pseudotime analysis]]></category>
		<category><![CDATA[single-cell RNA sequencing]]></category>
		<category><![CDATA[T cell exhaustion]]></category>
		<category><![CDATA[tarlatamab]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<category><![CDATA[tumor-infiltrating lymphocytes]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=414573</guid>

					<description><![CDATA[A single-cell multi-omic atlas of neuroendocrine carcinoma of the cervix identifies DLL3 as a driver of immune evasion and validates DLL3-targeted therapy in patient-derived organoid models.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">414573</post-id>	</item>
		<item>
		<title>How Cancer-Causing Viruses Hijack the Notch Signaling Pathway</title>
		<link>https://bioengineer.org/how-cancer-causing-viruses-hijack-the-notch-signaling-pathway/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 09 Oct 2026 14:42:00 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[carcinogenesis]]></category>
		<category><![CDATA[EBV]]></category>
		<category><![CDATA[EMT]]></category>
		<category><![CDATA[gamma-secretase inhibitors]]></category>
		<category><![CDATA[HBV]]></category>
		<category><![CDATA[HCV]]></category>
		<category><![CDATA[HPV]]></category>
		<category><![CDATA[HTLV-1]]></category>
		<category><![CDATA[KSHV]]></category>
		<category><![CDATA[NICD]]></category>
		<category><![CDATA[Notch Signaling]]></category>
		<category><![CDATA[oncogenic viruses]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=410698</guid>

					<description><![CDATA[A new review details how six major human oncoviruses dysregulate the Notch signaling pathway to drive proliferation, apoptosis resistance, and malignant transformation.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">410698</post-id>	</item>
		<item>
		<title>Exploding immune cells may explain why prostate drug therapy fails in some men</title>
		<link>https://bioengineer.org/exploding-immune-cells-may-explain-why-prostate-drug-therapy-fails-in-some-men/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Thu, 08 Oct 2026 14:30:29 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[5-alpha-reductase inhibitors]]></category>
		<category><![CDATA[Benign Prostatic Hyperplasia]]></category>
		<category><![CDATA[Cellular Senescence]]></category>
		<category><![CDATA[club-cell reprogramming]]></category>
		<category><![CDATA[GSDMD]]></category>
		<category><![CDATA[HMGB1–AGER signaling]]></category>
		<category><![CDATA[macrophage pyroptosis]]></category>
		<category><![CDATA[MIF–CD74 axis]]></category>
		<category><![CDATA[Notch Signaling]]></category>
		<category><![CDATA[PM-13 gene signature]]></category>
		<category><![CDATA[single-cell RNA sequencing]]></category>
		<category><![CDATA[Spatial transcriptomics]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=407682</guid>

					<description><![CDATA[A new study shows that 5-alpha-reductase inhibitor therapy can trigger macrophage pyroptosis, HMGB1–AGER-driven epithelial senescence and club-cell reprogramming in the prostate, explaining why some patients with benign prostatic hyperplasia progress despite treatment.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">407682</post-id>	</item>
		<item>
		<title>New Spatial Transcriptomics Tool Maps Gene Expression Across Tissue Boundaries in the Developing Mouse Brain</title>
		<link>https://bioengineer.org/new-spatial-transcriptomics-tool-maps-gene-expression-across-tissue-boundaries-in-the-developing-mouse-brain/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 05 Oct 2026 16:14:15 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Cell Adhesion]]></category>
		<category><![CDATA[developing mouse brain]]></category>
		<category><![CDATA[dorsal pallium]]></category>
		<category><![CDATA[meninges]]></category>
		<category><![CDATA[neurodevelopment]]></category>
		<category><![CDATA[Notch Signaling]]></category>
		<category><![CDATA[REBOSEP]]></category>
		<category><![CDATA[Spatial transcriptomics]]></category>
		<category><![CDATA[Stereo-seq]]></category>
		<category><![CDATA[tissue boundaries]]></category>
		<category><![CDATA[Visium HD]]></category>
		<category><![CDATA[Wnt Signaling]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=402838</guid>

					<description><![CDATA[Researchers have developed REBOSEP, a computational workflow that maps gene expression as a continuous signal across tissue boundaries and reveals spatially regulated developmental, angiogenic, and disease-related pathways in the embryonic mouse brain.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">402838</post-id>	</item>
		<item>
		<title>New Wave of Targeted and Immune Therapies Reshapes Marginal Zone Lymphoma Care</title>
		<link>https://bioengineer.org/new-wave-of-targeted-and-immune-therapies-reshapes-marginal-zone-lymphoma-care/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 05 Oct 2026 04:02:23 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[antibody-drug conjugates]]></category>
		<category><![CDATA[B-cell lymphoma]]></category>
		<category><![CDATA[BCL-2 inhibitors]]></category>
		<category><![CDATA[bispecific antibodies]]></category>
		<category><![CDATA[BTK inhibitors]]></category>
		<category><![CDATA[CAR-T therapy]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[marginal zone lymphoma]]></category>
		<category><![CDATA[NF-κB signaling]]></category>
		<category><![CDATA[Notch Signaling]]></category>
		<category><![CDATA[PI3K inhibitors]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=401824</guid>

					<description><![CDATA[A new review in Annals of Hematology details how molecular profiling and a growing arsenal of targeted and immune-based therapies are transforming the treatment of marginal zone lymphoma.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">401824</post-id>	</item>
		<item>
		<title>The Hidden RNA Master Switch That Behaves Differently in Every Cancer</title>
		<link>https://bioengineer.org/the-hidden-rna-master-switch-that-behaves-differently-in-every-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sun, 04 Oct 2026 11:06:33 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer biomarker]]></category>
		<category><![CDATA[ceRNA axis]]></category>
		<category><![CDATA[Chemotherapy Resistance]]></category>
		<category><![CDATA[chromosome 21]]></category>
		<category><![CDATA[long non-coding RNA]]></category>
		<category><![CDATA[microRNA host gene]]></category>
		<category><![CDATA[MIR99AHG]]></category>
		<category><![CDATA[Notch Signaling]]></category>
		<category><![CDATA[prognosis]]></category>
		<category><![CDATA[TGF-beta/SMAD]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Wnt/beta-catenin]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=400831</guid>

					<description><![CDATA[A new review reveals how the long non-coding RNA MIR99AHG acts as a multifunctional host gene and regulatory hub whose expression can predict prognosis and treatment response differently across cancer types.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">400831</post-id>	</item>
		<item>
		<title>Impact of Patient Variability on Vascular Tissue Engineering</title>
		<link>https://bioengineer.org/impact-of-patient-variability-on-vascular-tissue-engineering/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 09 Nov 2025 00:03:34 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Notch Signaling]]></category>
		<category><![CDATA[Patient Variability]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<category><![CDATA[Vascular Tissue Engineering]]></category>
		<guid isPermaLink="false">https://bioengineer.org/impact-of-patient-variability-on-vascular-tissue-engineering/</guid>

					<description><![CDATA[Emerging research in the realm of biomedicine is forging a new path in the field of vascular tissue engineering. The significance of understanding the interplay between patient variability and Notch signaling during the in situ vascular tissue engineering process has been comprehensively analyzed in a recent study. The work, led by researchers van Asten, Sahlgren, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">293762</post-id>	</item>
	</channel>
</rss>
